LITERATURA KOJU JE POTREBNO STAVITI SA PREZENTACIJAMA ZA SVAKI TEST

Test: **Pristup pacijentu sa kardiovaskularnom bolešću – izazov za lekara u opštoj medicini**

Literatura:

1. Visseren FLJ. Mach F, Smulders YV, Carballo D, in sar .2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). European Heart Journal (2021) 42, 32273337

2. Mancia, Kreutz et al.: 2023 ESH Guidelines for the management of arterial hypertension;Journal of Hypertension 2023, 41:000–000

3. 2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk.European Heart Journal (2019)00,1−78 doi:10.1093/eurheartj/ehz455

4. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. ESC Scientific Document Group, 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal. 2023; 44(37):3627–3639, https://doi.org/10.1093/eurheartj/ehad195.

5. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071.

Test: **Mesto lekara primarne zdravstvene zaštite u prevenciji, dijagnostici i lečenju predijabetesa i tipa 2 dijabetes melitusa**

Literatura:

1. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes - 2023. Diabetes Care 2023;46(Suppl. 1):S19-S40

2. Mannucci E, Caiulo C, Naletto L, Madama G, Monami M. Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network metaanalysis of randomized controlled trials. Endocrine 2021;74:508–517.

3. Leigh Perreault , Prediabetes, Endotext, March 3, 2022

4. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 Nov 1;45(11):2753-2786.

doi: 10.2337/dci22-0034.

5. Carel W le Roux et al: the SCALE Obesity Prediabetes NN8022-1839 Study Group : 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial, Th Lancet, February 22, 2017

Test: **Uloga lekara opšte medicine u prevenciji, ranom otkrivanju i dijagnostici hronične bolesti bubrega**

Literatura:

1. Evans M, Lewis RD, Morgan AR, Whyte MB, Hanif W, Bain SC, et al. A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives. Adv Ther. 2022;39(1):33-43.

2. Kam-Tao Li P, Garcia-Garcia G, Siu-Fai L, Andreoli S, Wing-Shing Fung W, et al. Kidney Health for Everyone Everywhere - from Prevention to Detection and Equitable Access to Care. West Afr J Med. 2020;37(4):368-376.

3. Luyckx VA, Cherney DZI, Bello AK. Preventing CKD in Developed Countries

Kidney Int Rep. 2019; 18;5(3):263-277.

4. Hannedouche T, Rossignol P, Darmon P, Halimi JM, Vuattoux P, Hagege A, et al. Early diagnosis of chronic kidney disease in patients with diabetes in France: multidisciplinary expert opinion, prevention value and practical recommendations. Postgrad Med. 2023;135(7):633-645.

5. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021; 99(3S). |

6. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022; 102(5S).

Test: **Polifarmacija – interakcije i neželjena dejstva lekova**

Literatura:

1. Joseph P. McGowan, Steven M. Fine, Samuel T. Merrick, Asa E. Radix, Rona M. Christopher J. Hoffmann, Charles J. Gonzalez, Resource: ART Drug-Drug Interactions, Date of original publication: April 25, 2019

2. Heather E. Barry & Carmel M. Hughes, An Update on Medication Use in Older Adults: a Narrative Review, Epidemiology of Aging (K Lapane, Section Editor), Open access, Published: 20 July 2021, Volume 8, pages 108–115, (2021)

3. Przemysław Kardas, Alpana Mair, Derek Stewart and Paweł Lewek for SIMPATHY Consortium, Optimizing polypharmacy management in the elderly: a comprehensive European benchmarking survey and the development of an innovative online benchmarking application, Original Research

PUBLISHED 17 October 2023, DOI 10.3389/fphar.2023.1254912

4. PRAVILNIK O NAČINU PRIJAVLJIVANJA, PRIKUPLJANJA I PRAĆENJA NEŽELJENIH REAKCIJA NA LEKOVE ("Sl. glasnik RS", br. 64/2011, 75/2017, 82/2017 - ispr. i 107/2023),

<https://www.paragraf.rs/propisi/pravilnik-o-nacinu-prijavljivanja-prikupljanja-i-pracenja-nezeljenih-reakcija-na-lekove.html>

5. Inamul Haq, Mohammad IsmailiD, Fahadullah Khan, Qasim Khan, Zahid Ali, Sidra Noo, Prevalence, predictors and outcomes of potential drug-drug interactions in left ventricular failure: considerable factors for quality use of medicines, Braz. J. Pharm. Sci. 2020;56: e18326, <https://doi.org/10.1590/s2175-97902020000218326>